^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    trastuzumab-IFN-β mutein

    i
    Other names: trastuzumab-IFN-β mutein, GNP101
    Company:
    Genopharm
    Drug class:
    HER2 inhibitor
    Related drugs:
    3years
    [VIRTUAL] HER2-targeted interferon-beta-1a mutein, a potent immunocytokine for the treatment of HER2-positive cancers (AACR 2021)
    We have characterized and evaluated the antitumor properties of trastuzumab-IFN-β mutein in HER2-expressing cancers. Since IFN-β activates antitumor immune responses, it is expected to be administered in combination with immunotherapeutic drugs. Therefore, the study suggests that trastuzumab-IFN-β mutein is a promising candidate for the treatment of HER2-positive carcinoma.
    Late-breaking abstract
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • trastuzumab-IFN-β mutein